PCRX250117C15000
- 7.20
- +0.40+5.88%
Pacira BioSciences Newsroom
Express News | RBC Capital Reiterates Sector Perform on Pacira BioSciences, Maintains $18 Price Target
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly
Pacira BioSciences Analyst Ratings
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Sell Rating
Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Raises Target Price to $30
Express News | Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $30
Raymond James Maintains Pacira BioSciences(PCRX.US) With Hold Rating
Sector Update: Health Care Stocks Weaker Late Afternoon
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Express News | Pacira Biosciences Shares Are Trading Higher After the Company Reported a Preliminary Year-over-year Increase in FY25 Revenue
Express News | Pacira Biosciences: Prelim Q4 Exparel Net Product Sales of $147.7 Mln
Express News | Pacira Biosciences: Sees Double-Digit Compounded Annual Growth Rate in Product Revenue by 2030
Pacira Announces New Five-Year Objectives to Accelerate Transition Into an Innovative Biopharmaceutical Organization
Express News | Pacira Biosciences FY Revenue USD 701 Million Vs. IBES Estimate USD 694.6 Million
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
Pacira BioSciences Secures FDA Approval For New Iovera SmartTip to Manage Chronic Low Back Pain
Express News | Pacira Biosciences Receives FDA 510K Clearance for New Iovera° Smarttip to Manage Chronic Low Back Pain via Long-Lasting Medial Branch Nerve Block
RBC Raises Price Target on Pacira Biosciences to $18 From $16, Keeps Sector Perform Rating